GSK.L: Summary for GLAXOSMITHKLINE PLC ORD 25P - Yahoo Finance

UK Markets closed

GlaxoSmithKline plc (GSK.L)


LSE - LSE Delayed price. Currency in GBp
Add to watchlist
1,558.50-7.50 (-0.48%)
At close: 5:05PM BST
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous close1,566.00
Open1,566.00
Bid1,545.00 x 175400
Ask1,584.00 x 417900
Day's range1,543.15 - 1,567.00
52-week range1,363.00 - 1,745.56
Volume10,031,036
Avg. volume8,748,006
Market cap75.65B
Beta1.19
PE ratio (TTM)83.79
EPS (TTM)N/A
Earnings dateN/A
Dividend & yield1.01 (4.94%)
Ex-dividend dateN/A
1y target estN/A
  • Fool.co.uk5 hours ago

    Last chance to buy GlaxoSmithKline plc for under £16?

    Is now the perfect time to buy a stake in GlaxoSmithKline plc (LON:GSK)?

  • Reuters - UK Focus10 hours ago

    AstraZeneca committed to UK, despite market challenges

    AstraZeneca (NYSE: AZN - news) 's chief executive said on Thursday his company remained "very committed" to investment in Britain, despite challenges in the UK market. Drugmakers are concerned at low healthcare spending and limited use of new drugs in the National Health Service, which results in French and German patients being five times more likely to receive a newly launched medicine than those in Britain. Industry is also worried about the impact of the country's decision to leave the European Union, which has created significant regulatory uncertainty.

  • Reuters10 hours ago

    AstraZeneca committed to UK, despite market challenges

    AstraZeneca's chief executive said on Thursday his company remained "very committed" to investment in Britain, despite challenges in the UK market. Drugmakers are concerned at low healthcare spending and limited use of new drugs in the National Health Service, which results in French and German patients being five times more likely to receive a newly launched medicine than those in Britain. Industry is also worried about the impact of the country's decision to leave the European Union, which has created significant regulatory uncertainty.